Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20751266 | 0.87 | MTNR1A (0.45) | KDM4AKDM4CCMA1DAOMTNR1A | |
| SCHEMBL16578609 | 0.81 | RAB9A (0.49) | TDP1 | |
| SCHEMBL16578613 | 0.81 | ADORA2A (0.46) | KDM4AKDM4CDAOADORA3ADORA2A | |
| SCHEMBL16578604 | 0.80 | MEN1 (0.40) | KDM4CTDP1DAO | |
| SCHEMBL16578558 | 0.80 | KDM4A (0.50) | KDM4AKDM4CDAOMTNR1A | |
| SCHEMBL20750987 | 0.79 | SOX18 (0.45) | ADORA3ADORA2AADORA1 | |
| SCHEMBL16578607 | 0.76 | COMT (0.46) | DAOMCL1ADORA3ADORA2AADORA1 | |
| SCHEMBL20751315 | 0.73 | ALDH1A1 (0.34) | CMA1MCL1 | |
| SCHEMBL16578557 | 0.72 | ALDH1A1 (0.44) | ADORA3 | |
| SCHEMBL16578524 | 0.72 | MTNR1A (0.41) | KDM4AKDM4CCMA1DAOMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364226-B2 | Pyridazinone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| EP-3030549-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | ALIOS BIOPHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364226-B2 | Pyridazinone compounds and uses thereof | PDXK, PNPO, PLPBP | KDM4A 1626/4885KDM4C 1580/4885COPS5 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.